Background: The coexistence of malignancies close to each other on the skin has been occasionally reported. The concept of field cancerogenesis applies to such cases. Given the purported mechanism of action of imiquimod, it should not be surprising that this treatment could inhibit epidermal field cancerogenesis. Aim: To assess the effect of imiquimod applied twice weekly on incipient bowenoid changes disclosed in the vicinity of basal cell carcinomas. Materials and Method: Biopsies were taken before treatment and after 4–6 weeks and 12 weeks of imiquimod treatment. Results: Large atypical bowenoid keratinocytes and dyskeratotic cells were cleared in time while factor-XIIIa-positive dermal dendrocytes appeared boosted and admixed with a brisk lymphocytic infiltration. Conclusion: Epidermal field cancerogenesis appears to be controlled by imiquimod. Dermal dendrocytes might play a pivotal role in this regression phenomenon.

1.
Woodhead AD, Setlow RB, Tanaka M: Environmental factors in nonmelanoma and melanoma skin cancer. J Epidemiol 1999;9(suppl 6):S102–S114.
2.
Bhawan J, Mehregan AH, Jung-Legg Y, Gellis SE: Pigmented basal cell carcinoma and superficial spreading malignant melanoma: An unusual combination. J Cutan Pathol 1984;11:471–475.
3.
Coskey RJ, Mehregan AH: The association of basal cell carcinomas with other tumors. J Dermatol Surg Oncol 1987;13:553–555.
4.
Sina B, Samorodin C: Basal cell carcinoma surrounded by lentigo maligna. Cutis 1989;44:81–82.
5.
Schallreuter KU, Levening C, Berger J: Cutaneous malignant melanomas with other coexisting neoplasms: A true association? Dermatology 1993;186:12–17.
6.
Boyd AS, Rapini RP: Cutaneous collision tumors: An analysis of 69 cases and review of the literature. Am J Dermatopathol 1994;16:253–257.
7.
Marghoob AA, Slade J, Kopf AW, Salopek TG, Rigel DS, Bart RS: Risk of developing multiple primary cutaneous melanomas in patients with the classic atypical-mole syndrome: A case-control study. Br J Dermatol 1996;135:704–711.
8.
Levi F, La Vecchia C, Randimbison L, Te VC, Erler G: Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer 1997;72:776–779.
9.
Piérard GE, Fazaa B, Henry F, Kamoun MR, Piérard-Franchimont C: Collision of primary malignant neoplasms of the skin: The malignant melanoma-basal cell carcinoma connection. Dermatology 1997;194:378–379.
10.
Savoia P, Quaglino P, Verrone A, Bernengo MG: Multiple primary melanomas: Analysis of 49 cases. Melanoma Res 1998;8:361–366.
11.
Wassberg C, Thorn M, Yuen J, Ringborg U, Hakulinen T: Second primary cancers in patients with squamous cell carcinoma of the skin: A population based study in Sweden. Int J Cancer 1999;80:511–515.
12.
Bower CP, Lear JT, Bygrave S, Etherington D, Harvey I, Archer CB: Basal cell carcinoma and risk of subsequent malignancies: A cancer registry-based study in southwest England. J Am Acad Dermatol 2000;42:988–991.
13.
Hemminki K, Dong C: Subsequent cancers after in situ and invasive squamous cell carcinoma of the skin. Arch Dermatol 2000;136:647–651.
14.
Milan T, Pukkala E, Verkasalo PK, Kaprio J, Jansen CT, Koskenvuo M, Teppo L: Subsequent primary cancers after basal-cell carcinoma: A nationwide study in Finland from 1953 to 1995. Int J Cancer 2000;87:283–288.
15.
Slaughter DP, Southwick HW, Smejkal W: ‘Field cancerization’ in oral stratified squamous epithelium: Clinical implications of multicentric origin. Cancer 1953;6:963–968.
16.
Sagman U, Lishner M, Maki E, Shepherd FA, Haddad R, Evans WK, De Boer G, Payne D, Pringle JF, Yeoh JL: Second primary malignancies following diagnosis of small-cell lung cancer. J Clin Oncol 1992;10:1525–1533.
17.
Carlson JA, Scott D, Wharton J, Sell S: Incidental histopathologic pattern: Possible evidence of ‘field cancerisation’ surrounding skin tumors. Am J Dermatopathol 2001;23:494–497.
18.
Guenthner ST, Hurwitz RM, Buckel LJ, Gray HR: Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation. J Am Acad Dermatol 1999;41:443–448.
19.
Carli P, Massi D, Santucci M, Biggeri A, Giannotti B: Cutaneous melanoma histologically associated with a nevus and melanoma de novo have a different profile of risk: Results from a case-control study. J Am Acad Dermatol 1999;40:549–557.
20.
Miller RL, Gerster KF, Owens ML, Slade HB, Tomai MA: Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol 1999;21:1–14.
21.
Sauder DN: Immunomodulatory and pharmacological properties of imiquimod. J Am Acad Dermatol 2000;43:S6–S11.
22.
Eedy DJ: Imiquimod: A potential role in dermatology ? Br J Dermatol 2002;147:1–6.
23.
Stockfleth E, Meyer T, Benninghoff B, Christophers E: Successful treatment of actinic keratosis with imiquimod cream 5%: A report of six cases. Br J Dermatol 2001;144:1050–1053.
24.
Persaud A, Lebwohl M: Imiquimod cream in the treatment of actinic keratoses. J Am Acad Dermatol 2002;47:S236–S239.
25.
Diaz-Arrastia C, Arany I, Robazetti SC, Dinh TV, Gatalica Z, Tyring SK, Hannigan E: Clinical and molecular responses in high-grade intraepithelial neoplasia treated with imiquimod 5%. Clin Cancer Res 2001;7:3031–3033.
26.
Hengge UR, Stark R. Topical imiquimod to treat intraepidermal carcinoma. Arch Dermatol 2001;137:709–711.
27.
Mackenzie-Wood A, Kossard S, de Launey J, Wilkinson B, Owens MI: Imiquimod 5% cream in the treatment of Bowen’s disease. J Am Acad Dermatol 2001;44:462–470.
28.
Cook-Bolden F, Weinberg JM: Topical imiquimod 5% cream in the treatment of Bowen’s disease of the penis. J Am Acad Dermatol 2002;46:146–147.
29.
Gutzmer R, Kaspari M, Vogelbruch M, Kiehl P, Kapp A, Werfel T, Brodersen JP: Successful treatment of anogenital Bowen’s disease with the immunomodulator imiquimod, and monitoring of therapy by DNA image cytometry. Br J Dermatol 2002;147:160–165.
30.
Thai KE, Sinclair RD: Treatment of Bowen’s disease of the penis with imiquimod. J Am Acad Dermatol 2002;46:470–471.
31.
Schroeder TL, Sengelmann RD: Squamous cell carcinoma in situ of the penis successfully treated with imiquimod 5% cream. J Am Acad Dermatol 2002;46:545–548.
32.
Kagy MK, Amonette R: The use of imiquimod 5% cream for the treatment of superficial basal cell carcinomas in a basal cell naevus syndrome patient. Dermatol Surg 2000;26:577–578.
33.
Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox TI, Owens ML and the Australasian Multicentre Trial Group: Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: Results of a multicentre 6-week dose-response trial. J Am Acad Dermatol 2001;44:807–813.
34.
Quatresooz P, Piérard GE: Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol, in press.
35.
Arrese JE, Paquet P, Claessens N, Piérard-Franchimont C, Piérrard GE: Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol 2001;28:131–134.
36.
Hermanns-Lê T, Paquet P, Nikkels AF, Piérard-Franchimont C, Piérard GE: Prolonged imiquimod treatment and graft-versus-host reaction: Histological mimicry in the skin infiltration pattern of the monocyte-macrophage-dendrocyte lineage. Dermatology 2003;206:361–365.
37.
Zipori D: Stroma cells in tumor growth and regression. Cancer J 1990;3:164–169.
38.
Al-Saleh W, Delvenne P, Arrese JA, Nikkels AF, Piérard GE, Boniver J: Inverse modulation of intraepithelial Langerhans’ cells and stromal macrophage/dendrocyte populations in human papillomavirus-associated squamous intraepithelial lesions of the cervix. Virchows Arch 1995;27:41–48.
39.
Arrese JE, Piérard GE: Factor XIIIa-positive dendrocytes and the dermal microvascular unit. Dermatologica 1990;180:51–53.
40.
Piérard-Franchimont C, Arrese JE, Nikkels AF, Al-Saleh W, Delvenne P, Piérard GE: Factor XIIIa-positive dermal dendrocytes and proliferative activity of cutaneous cancers. Virchows Arch 1996;429:43–48.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.